When the U.S. Food and Drug Administration (FDA) issued a complete response letter in May 2023, it indicated that the agency could not approve the biologics license application (BLA) for a Non-Muscle-Invasive Bladder Cancer (NMIBC) vaccine candidate, thousands of people impacted by this common cancer were disappointed.
Read More